These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19515090)

  • 1. The cost-effectiveness of computer-assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study.
    Jowett S; Bryan S; Poller L; VAN DEN Besselaar AM; VAN DER Meer FJ; Palareti G; Shiach C; Tripodi A; Keown M; Ibrahim S; Lowe G; Moia M; Turpie AG; Jespersen J
    J Thromb Haemost; 2009 Sep; 7(9):1482-90. PubMed ID: 19515090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage.
    Poller L; Keown M; Ibrahim S; Lowe G; Moia M; Turpie AG; Roberts C; van den Besselaar AM; van der Meer FJ; Tripodi A; Palareti G; Jespersen J
    Br J Haematol; 2008 Oct; 143(2):274-83. PubMed ID: 18759767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage.
    Poller L; Keown M; Ibrahim S; Lowe G; Moia M; Turpie AG; Roberts C; van den Besselaar AM; van der Meer FJ; Tripodi A; Palareti G; Shiach C; Bryan S; Samama M; Burgess-Wilson M; Heagerty A; Maccallum P; Wright D; Jespersen J
    J Thromb Haemost; 2008 Jun; 6(6):935-43. PubMed ID: 18489430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program.
    Poller L; Keown M; Ibrahim S; Lowe G; Moia M; Turpie AG; Roberts C; van den Besselaar AM; van der Meer FJ; Tripodi A; Palareti G; Shiach C; Bryan S; Samama M; Burgess-Wilson M; Heagerty A; Maccallum P; Wright D; Jespersen J;
    Thromb Haemost; 2009 Mar; 101(3):487-94. PubMed ID: 19277410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling.
    Connock M; Stevens C; Fry-Smith A; Jowett S; Fitzmaurice D; Moore D; Song F
    Health Technol Assess; 2007 Oct; 11(38):iii-iv, ix-66. PubMed ID: 17903392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of therapy with vitamin K antagonists in Italian patients aged 80 years or older: a multicentre retrospective study comparing the Zeus algorithm with the PARMA algorithm or manual therapy.
    Cafolla A; Manisco L; Baldacci E; Porcu A; Campanelli M; Cursano MC; Rossi E; Dragoni F; Foà R
    Drugs Aging; 2015 Mar; 32(3):235-41. PubMed ID: 25721557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.
    Poller L; Shiach CR; MacCallum PK; Johansen AM; Münster AM; Magalhães A; Jespersen J
    Lancet; 1998 Nov; 352(9139):1505-9. PubMed ID: 9820298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
    Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
    JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial.
    Magnuson EA; Chinnakondepalli K; Vilain K; Kearon C; Julian JA; Kahn SR; Goldhaber SZ; Jaff MR; Kindzelski AL; Herman K; Brady PS; Sharma K; Black CM; Vedantham S; Cohen DJ
    Circ Cardiovasc Qual Outcomes; 2019 Oct; 12(10):e005659. PubMed ID: 31592728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amaze: a double-blind, multicentre randomised controlled trial to investigate the clinical effectiveness and cost-effectiveness of adding an ablation device-based maze procedure as an adjunct to routine cardiac surgery for patients with pre-existing atrial fibrillation.
    Sharples L; Everett C; Singh J; Mills C; Spyt T; Abu-Omar Y; Fynn S; Thorpe B; Stoneman V; Goddard H; Fox-Rushby J; Nashef S
    Health Technol Assess; 2018 Apr; 22(19):1-132. PubMed ID: 29701167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].
    Della Palma P; Moresco L; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 3):e1-43. PubMed ID: 23139174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy.
    Ageno W; Johnson J; Nowacki B; Turpie AG
    Thromb Haemost; 2000 Jun; 83(6):849-52. PubMed ID: 10896237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
    Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
    Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
    Pink J; Pirmohamed M; Lane S; Hughes DA
    Clin Pharmacol Ther; 2014 Feb; 95(2):199-207. PubMed ID: 24067746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation.
    Jowett S; Bryan S; Mant J; Fletcher K; Roalfe A; Fitzmaurice D; Lip GY; Hobbs FD
    Stroke; 2011 Jun; 42(6):1717-21. PubMed ID: 21512184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.